Review of Screening, Molecular Mechanism and Clinical Application of Sebaceous Carcinoma

Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v5i4.3319

Qinxue Pu, Yuchang Hu

The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China; Department of Pathology, Yichang Central People's Hospital, Yichang, Hubei, China

Abstract

Sebaceous carcinoma (SC) is relative rarity and variable clinical presentation. It’s difficult to diagnose. The screening of immunohistochemical markers, molecular mechanism analysis and clinical application of sebaceous carcinoma are the focus of current research. This paper aims to comprehensively comb and summarize the latest immunohistochemical markers, and deeply explore the molecular mechanisms and the treatment of sebaceous carcinoma. Through a review of the extensive literature, we found that immunohistochemical stains play an important role in the early diagnosis, formulation of individualed treatment plan and prognostic evaluation of sebaceous carcinoma.

Keywords

sebaceous carcinoma; immunohistochemistry; molecular mechanism; clinical application; biomarker

References

[1] Christopher K,Fahd Y,Roman S,et al. Current review of sebaceous cell carcinoma[J]. Current Opinion in Ophthalmology, 2018, 29:445–450DOI:10.1097/ICU.0000000000000505
[2] Cui Jiaojiao, Xia Heshun, Yang Chibing. Clinicopathological analysis of 7 cases of eyelid sebaceous gland carcinoma [J]. Journal of Practical Medical Technology, 2024,31(02):128-130+154.DOI:10.19522/j.cnki.1671-5098.2024.02.014.
[3] Wang Meihong, Ma Jianhui, Wang Tao, et al. Primary sebaceous carcinoma of the mandibular gingiva was reported and reviewed in the literature [J]. Cancer prevention and Treatment Research, 2019,46 (01): 93-95.
[4] Joanna K.M,Paul C.L,Chit Chow, et al. prame immunostain expression in seba source pathology so 2022 [J].Pathology,https://doi.org/10.1016/j.pathol.2022.03.003
[5] Fang Sangao, Ma Qiang, Wang Yuanyuan, et al. Clinicopathological analysis of sebaceous carcinoma of the eyelid [J]. Modern Medical Oncology, 2014,22 (07): 1557-1561.
[6] Liang Yuan, Yu Wenbo, Xiong Jianhui, et al. Progress in the molecular mechanism of aortic dissection [J]. Journal of Gannan Medical College, 2024,44 (04): 354-356 + 382.
[7] Wei Ruili. Evidence-based evaluation and study of molecular mechanism [D]. The Chinese Academy of Chinese Medical Sciences, 2023.DOI:10.27658/d.cnki.gzzyy. 2023.000044.
[8] He Jinwen. Anti-osteoporosis drug screening and Molecular Mechanism of targeting AXL [D]. Lanzhou University, 2023.DOI:10.27204/d.cnki.glzhu. 2023.000302.
[9] Doshi N ,Gond P ,Prasad T , et al.An unusual presentation of giant sebaceous cyst over the back: A case report.[J].Clinical case reports,2024,12(4):e8714-e8714.
[10] Daniele T ,Rudolf H .Phacomatosis spilosebacea: A new name for a distinctive binary genodermatosis.[J].Journal of the American Academy of Dermatology,2023,89(4):764-773.
[11] Tarun K ,Prerna T ,Nisha K , et al.Cytomorphology of sebaceous arcinoma of the eyelid: A short series of three cases with literature review.[J].Diagnostic cytopathology,2022,50(12):E361-E366.
[12] Subhra D ,U A M ,Jaya J S , et al.Lynch syndrome: An unusal case of familial cancer unearthed.[J].Indian journal of pathology & microbiology,2022,65(2):465-467.
[13] Oscar T ,Carlos J C ,Pedro J R , et al.Benign follicular tumors.[J].Anais brasileiros de dermatologia,2015,90(6):780-96; quiz 797-8.
[14] Hee Young Na,Ji-Young Choe,Seon Ah Shin, et al. Proposal of a Provisional Classification of Sebaceous Carcinoma Based on Hormone [J]. Am J Surg Pathol 2016;40:1622–1630.
[15] Maelle S,Muhammad S,Rana El H, et al.PD-L1 expression in sebaceous carcinomas.[J]Cancer Immunology, Immunotherapy .https://doi.org/10.1007/s00262-020-02821-3
[16] Rachel L,Kimberly L,Eva A.Sebaceous Carcinoma: Review of the Literature.[J]Dermatol Surg 2015;41:1–15,DOI: 10.1097/DSS.0000000000000152.

Copyright © 2025 Qinxue Pu, Yuchang Hu

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License